LDN Pharma Limited
London, GB· latest recorded location
LDN Pharma Limited is named on 8 US grants and 17 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 8
- Published applications
- 17
- Inventors
- 7
- Granted in 2026 so far
- 1
- Most recent grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2020 | 0 | 5 |
| 2021 | 0 | 1 |
| 2022 | 2 | 2 |
| 2023 | 0 | 3 |
| 2024 | 3 | 4 |
| 2025 | 2 | 2 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 25 documents
- A61KMedicines and medical preparations25
- A61PTherapeutic uses of medicines25
- G01NInvestigating or analysing materials by determining their chemical or physical properties11
- C07DHeterocyclic compounds2
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms2
- Y02ATechnologies for adaptation to climate change1
Recent patents
- Agent that increases the expression of the BCL2-associated agonist of cell death for the treatment of cancer28 Apr 2026US 12,611,405 B2
- Method of monitoring treatment16 Dec 2025US 12,497,663 B2
- Cancer treatment10 Jun 2025US 12,324,805 B2
- Priming of cancer cells with low dose naltrexone19 Nov 2024US 12,144,807 B2
- Autoimmune therapy9 Jul 2024US 12,029,737 B2
- Naltrexone for boosting the therapeutic utilty of 5-ht receptor agonists11 Sep 2025US 2025/0281481 A1
- Priming of cancer cells with low dose naltrexone30 Jan 2025US 2025/0032481 A1
- Naltrexone for improving the effectiveness of 5-ht receptor subtype 2a, 2b or 2c agonists5 Sep 2024US 2024/0293395 A1
- Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 329 Aug 2024US 2024/0285612 A1
- Treatment for autoimmune diseases29 Aug 2024US 2024/0285613 A1
Most cited
By later US patents